Genmab A/S (GMAB) vs Teva Pharmaceutical Industries (TEVA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Teva Pharmaceutical Industries (TEVA) has outperformed Genmab A/S (GMAB) over the past year, gaining 95.2% versus a gain of 12.3%. Over five years, TEVA leads with a +304.8% price change compared with -17.5% for GMAB. Teva Pharmaceutical Industries is the larger company by market cap ($45.78 billion vs $22.17 billion), about 2.1 times the size, while Genmab A/S is growing revenue faster (+19.2% vs +4.3%).
On valuation, Teva Pharmaceutical Industries trades at a lower forward P/E (12.7x vs 23.6x for Genmab A/S). Genmab A/S converts more of its revenue into profit, with a net margin of 25.9% versus 8.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GMAB | TEVA |
|---|---|---|
| Share price | $36.05 | $39.25 |
| Market cap | $22.17B | $45.78B |
| 1-day change | -1.64% | +0.18% |
| YTD return | +18.99% | +25.54% |
| 1-year return | +12.29% | +95.22% |
| 5-year return | -17.51% | +304.75% |
| P/E ratio (TTM) | 28.39 | 65.42 |
| Forward P/E | 23.64 | 12.70 |
| EPS (TTM) | $1.27 | $0.60 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $3.72B | $17.26B |
| Revenue growth (YoY) | +19.19% | +4.32% |
| Net income (latest FY) | $963.00M | $1.41B |
| Gross margin | 93.60% | 51.79% |
| Operating margin | 28.63% | 12.50% |
| Net margin | 25.89% | 8.17% |
| 52-week high | $40.17 | $40.79 |
| 52-week low | $23.62 | $18.83 |
| Distance from 52-week high | -10.26% | -3.78% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +19.89% | +15.41% |
| Average volume | 2.80M | 5.29M |
| Shares outstanding | 614.90M | 1.17B |
| Employees | 3,119 | 31,173 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Teva Pharmaceutical Industries is about 2.1 times larger than Genmab A/S by market value ($45.78B vs $22.17B).
- TEVA has outperformed GMAB by 82.9 percentage points over the past year.
- Teva Pharmaceutical Industries trades at a higher earnings multiple (65.4x vs 28.4x trailing P/E).
- Genmab A/S is more profitable, keeping 25.9 cents of every revenue dollar as net income versus 8.2 cents for Teva Pharmaceutical Industries.
- Genmab A/S grew revenue faster in its latest fiscal year (+19.19% vs +4.32%).
About Genmab A/S
GMAB stock →Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy.
Health Care · Biotechnology: Pharmaceutical Preparations · 3,119 employees
About Teva Pharmaceutical Industries
TEVA stock →Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.
Health Care · Biotechnology: Pharmaceutical Preparations · 31,173 employees
GMAB vs TEVA FAQ
Which is bigger, Genmab A/S or Teva Pharmaceutical Industries?
Teva Pharmaceutical Industries (TEVA) is larger, with a market capitalization of $45.78B compared with $22.17B for Genmab A/S (GMAB).
Which stock has performed better over the past year, GMAB or TEVA?
TEVA returned +95.22% over the past 12 months, compared with +12.29% for GMAB (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, GMAB or TEVA?
GMAB has the lower trailing P/E at 28.4, versus 65.4 for TEVA. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Genmab A/S and Teva Pharmaceutical Industries in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.